Sanguina is a leading biotech company focused on advancing accessible digital and at-home health platforms for rapid home-based testing and disease management. Founded in 2019, Sanguina aims to empower individuals by providing innovative solutions for diagnosing, monitoring, and managing wellness and chronic conditions. With a team of experienced scientists, engineers, and healthcare professionals, Sanguina is committed to positively impacting global healthcare.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/25/23 | $2,800,000 | Series A |
George Hornig Stephen Ippolito Veritus Holdings  | undisclosed |
